Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals gained 0.560% compared to yesterday.
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | 0.560% | -1.648% | 2.286% | -29.528% | 1.705% | -3.763% | -37.847% |
| Indivior plc | -2.170% | 0.000% | -10.000% | 136.842% | -10.000% | 21.348% | 256.201% |
| Viatris Inc. | -1.120% | 0.767% | 9.564% | 4.686% | 6.028% | 4.765% | -21.338% |
| Repligen Corp. | 1.060% | -1.682% | -2.726% | -13.038% | -2.449% | -17.557% | -22.460% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat